Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IMPACT-Crohn

ABSTRACT: Fecal microbiota transplantation to maintain remission in Crohn’s disease : a pilot randomized controlled study

PROVIDER: PRJEB33031 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3374480.fastq.gz	Fastqsanger.gz
	ERR3374490.fastq.gz	Fastqsanger.gz
	ERR3374500.fastq.gz	Fastqsanger.gz
	ERR3374510.fastq.gz	Fastqsanger.gz
	ERR3374520.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 116

Similar Datasets

A functional genomics predictive network model identifies regulators of inflammatory bowel disease: Microarray Analysis of Human Blood and Intestinal Biopsy Samples from a Phase 2b, Double-blind, Placebo-controlled Study of Ustekinumab in Crohn's Disease

2017-07-07 | GSE100833 | GEO

Adipose derived stem cells (ASCs) methylation differences between Crohn Disease and No-Crohn individuals

Project description:Pathological expansion of adipose tissue (AT) is supported by adipocyte precursors, termed adipose-derived stem cells (ASCs). Elucidation of mechanisms underlying ASC function may lead to therapeutic interventions to use in cell therapy treatments on Crohn’s disease patients. Using epigenome-wide association studies, we explored the impact of Crohn’s disease on the methylation signature of human ASCs

2019-10-03 | GSE138311 | GEO

Impact of fecal microbiota transplantation (FMT) in 3 days-ABX-treated recipient mice using feces from 6 NSCLC patients at diagnosis.

Project description:This study aimed to analyze changes in gut microbiota composition in mice after transplantation of fecal microbiota (FMT, N = 6) from the feces of NSCLC patients by analyzing fecal content using 16S rRNA sequencing, 10 days after transplantation. Specific-pathogen-free (SPF) mice were used for each experiments (N=4) as controls.

2023-07-01 | E-MTAB-12812 | biostudies-arrayexpress

null

Project description:Fecal Microbiota Transplantation on Hypertension: an exploratory, multi-center, randomized, blinded, placebo-controlled trial

| PRJEB72385 | ENA

Project description:Microarray Analysis of Human Whole Blood and Intestinal Biopsy Samples from a Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Crohn’s Disease 329 Crohn's biopsies from multiple regions in the intestine of 87 anti TNFa refractory patients and blood samples from 204 patients at Week 0 prior to drug treatment are included in this study

2017-07-07 | E-GEOD-100833 | biostudies-arrayexpress

Myeloablation followed by autologous stem cell transplantation normalizes systemic sclerosis molecular signatures

Project description:This is global gene expression study of whole blood samples collected in the Cyclophosphamide Or Transplantation (SCOT) randomized controlled trial, as well as unaffected controls. Patients with diffuse cutaneous systemic sclerosis (scleroderma) received either myeloablation followed by autologous stem cell transplantation or intravenous cyclophosphamide

2019-07-10 | GSE130953 | GEO

Project description:Preliminary results from a multicenter, randomized trial using fecal microbial transplantation to induce remission in patients with Crohns disease

| PRJNA1178690 | ENA

Project description:Exploratory Study on the Effects of Fecal Microbial Transplantation and Probiotics on Gut Microbiota in Critically Ill Patients after Broad-Spectrum Antibiotic Treatment: A Pilot Randomized Controlled Trial

| PRJNA1166732 | ENA

Lengthening Adalimumab Dosing Interval in Quiescent Crohn’s Disease Patients

Project description:Crohn’s disease is a chronic inflammatory bowel disease. This disease can be treated with, among other things, biologicals such as adalimumab. Patients use adalimumab for a long time to maintain remission and to prevent relapse of the bowel inflammation. The disadvantages of this therapy are the high price and side effects (such as the higher risk of infection). Currently, adalimumab is given every 2 weeks, by injection under the skin. The optimal time between two injections has never been investigated before. Prior research in patients with rheumatoid arthritis shows that disease remission can be maintained with longer injection-intervals. Our hypothesis is that this is the same for Crohn’s disease patients. Our aim is to show non-inferiority of extending the adalimumab dosing interval, under strict disease monitoring in Crohn’s disease patients in sustained (>9 months) clinical remission, compared to standard care. During the trial,174 patients with stable Crohn’s disease will be divided into 2 groups. One group continues adalimumab injections with the same 2-week interval. And the other group will incrementally extend the interval to 4 weeks, under strict disease monitoring. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval. Thus, we will investigate whether, and for whom, it is safe to extend the adalimumab injection interval.

| 2245854 | ecrin-mdr-crc

Metagenome

Project description:Linking strain engraftment in fecal microbiota transplantation with maintenance of remission in Crohn's disease

| PRJNA625520 | ENA